Advances in Runx2 regulation and its isoforms

Ya lin Li, Zhousheng Xiao

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

During the last 10 years, we have witnessed major progress in skeleton biology. Runx2 is an accepted transcription factor essential for osteoblast development from mesenchymal stem cells and maturation into osteocytes and organize crucial events during bone formation. Alternations in Runx2 expression levels are associated with skeletal diseases. In vitro and in vivo studies have reported that multiple integrated complex path ways (such as Wnt/LRP5/β-catenin, BMP/Smads, 1, 25-(OH)2-vitaminD3/VDR/VDRE pathway, etc.) and several regulatory proteins (such as Msx2, Dlx5, Twists, etc.) play critical roles in modulating Runx2 gene expression, activity, and the subsequent bone formation. These findings provide novel insights through controlling osteoblast differentiation to treat osteoporosis or other bone diseases with altered bone mass by stimulating Runx2 expression. Further studies have shown that expression of RUNX2 is initiated from two promoters, the distal P1 promoter and the proximal P2 promoter. The alternative use of promoters gives rise to the genesis of two major protein isoforms with distinct amino termini, named as Runx2-TypeI and Runx2-TypeII. Here, we also review a complex spatio-temporal pattern of two major isoforms expressions and their possible function differences in skeleton development.

Original languageEnglish (US)
Pages (from-to)169-175
Number of pages7
JournalMedical Hypotheses
Volume68
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Osteoblasts
Osteogenesis
Skeleton
Protein Isoforms
Osteocytes
Catenins
Bone Diseases
Mesenchymal Stromal Cells
Osteoporosis
Transcription Factors
Gene Expression
Bone and Bones
Proteins
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Advances in Runx2 regulation and its isoforms. / Li, Ya lin; Xiao, Zhousheng.

In: Medical Hypotheses, Vol. 68, No. 1, 01.01.2007, p. 169-175.

Research output: Contribution to journalArticle

Li, Ya lin ; Xiao, Zhousheng. / Advances in Runx2 regulation and its isoforms. In: Medical Hypotheses. 2007 ; Vol. 68, No. 1. pp. 169-175.
@article{181bbd7d19164a649e2b3568923846ab,
title = "Advances in Runx2 regulation and its isoforms",
abstract = "During the last 10 years, we have witnessed major progress in skeleton biology. Runx2 is an accepted transcription factor essential for osteoblast development from mesenchymal stem cells and maturation into osteocytes and organize crucial events during bone formation. Alternations in Runx2 expression levels are associated with skeletal diseases. In vitro and in vivo studies have reported that multiple integrated complex path ways (such as Wnt/LRP5/β-catenin, BMP/Smads, 1, 25-(OH)2-vitaminD3/VDR/VDRE pathway, etc.) and several regulatory proteins (such as Msx2, Dlx5, Twists, etc.) play critical roles in modulating Runx2 gene expression, activity, and the subsequent bone formation. These findings provide novel insights through controlling osteoblast differentiation to treat osteoporosis or other bone diseases with altered bone mass by stimulating Runx2 expression. Further studies have shown that expression of RUNX2 is initiated from two promoters, the distal P1 promoter and the proximal P2 promoter. The alternative use of promoters gives rise to the genesis of two major protein isoforms with distinct amino termini, named as Runx2-TypeI and Runx2-TypeII. Here, we also review a complex spatio-temporal pattern of two major isoforms expressions and their possible function differences in skeleton development.",
author = "Li, {Ya lin} and Zhousheng Xiao",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.mehy.2006.06.006",
language = "English (US)",
volume = "68",
pages = "169--175",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Advances in Runx2 regulation and its isoforms

AU - Li, Ya lin

AU - Xiao, Zhousheng

PY - 2007/1/1

Y1 - 2007/1/1

N2 - During the last 10 years, we have witnessed major progress in skeleton biology. Runx2 is an accepted transcription factor essential for osteoblast development from mesenchymal stem cells and maturation into osteocytes and organize crucial events during bone formation. Alternations in Runx2 expression levels are associated with skeletal diseases. In vitro and in vivo studies have reported that multiple integrated complex path ways (such as Wnt/LRP5/β-catenin, BMP/Smads, 1, 25-(OH)2-vitaminD3/VDR/VDRE pathway, etc.) and several regulatory proteins (such as Msx2, Dlx5, Twists, etc.) play critical roles in modulating Runx2 gene expression, activity, and the subsequent bone formation. These findings provide novel insights through controlling osteoblast differentiation to treat osteoporosis or other bone diseases with altered bone mass by stimulating Runx2 expression. Further studies have shown that expression of RUNX2 is initiated from two promoters, the distal P1 promoter and the proximal P2 promoter. The alternative use of promoters gives rise to the genesis of two major protein isoforms with distinct amino termini, named as Runx2-TypeI and Runx2-TypeII. Here, we also review a complex spatio-temporal pattern of two major isoforms expressions and their possible function differences in skeleton development.

AB - During the last 10 years, we have witnessed major progress in skeleton biology. Runx2 is an accepted transcription factor essential for osteoblast development from mesenchymal stem cells and maturation into osteocytes and organize crucial events during bone formation. Alternations in Runx2 expression levels are associated with skeletal diseases. In vitro and in vivo studies have reported that multiple integrated complex path ways (such as Wnt/LRP5/β-catenin, BMP/Smads, 1, 25-(OH)2-vitaminD3/VDR/VDRE pathway, etc.) and several regulatory proteins (such as Msx2, Dlx5, Twists, etc.) play critical roles in modulating Runx2 gene expression, activity, and the subsequent bone formation. These findings provide novel insights through controlling osteoblast differentiation to treat osteoporosis or other bone diseases with altered bone mass by stimulating Runx2 expression. Further studies have shown that expression of RUNX2 is initiated from two promoters, the distal P1 promoter and the proximal P2 promoter. The alternative use of promoters gives rise to the genesis of two major protein isoforms with distinct amino termini, named as Runx2-TypeI and Runx2-TypeII. Here, we also review a complex spatio-temporal pattern of two major isoforms expressions and their possible function differences in skeleton development.

UR - http://www.scopus.com/inward/record.url?scp=33751103183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751103183&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2006.06.006

DO - 10.1016/j.mehy.2006.06.006

M3 - Article

VL - 68

SP - 169

EP - 175

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 1

ER -